Neil Goldsmith

Neil Goldsmith has been involved in the biotechnology industry since 2004. Neil began their career as the Co-founder, Managing Director & CEO of Evolva, where they led the company from a 3-person start-up to one of the world's leading synthetic biology companies. In 2018, they became the Co-founder of Double Bio, Board Member of Unibio, Director Strategy of BaseLaunch, and Advisor of River Stone Bio. Neil also co-founded Alentis Therapeutics, where they served as Chair. In 2021, they became the Co-founder of Gly-it, Aida Oncology, and Chosa Oncology. Throughout their career, Neil has been involved in developing breakthrough therapies, converting natural gas into protein, providing effective, affordable and environmentally benign methods of control, and building world class, early stage, therapeutic ventures.

Neil Goldsmith attended the University of Oxford from 1981 to 1984 and earned a BA Hons, 1st Class in Zoology (Balliol).